Skip to main
GMED

Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical (GMED) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 42%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Globus Medical is poised for a positive outlook driven by several key factors, including anticipated faster growth in the spine market and an increase in sales from its Enabling Technologies segment, which could lead to improved profit margins. The company's fourth-quarter performance, highlighted by a 10% growth largely due to strong U.S. spine sales, reinforces confidence in its revenue trends and signals potential upside to future guidance. Additionally, as Globus Medical capitalizes on integration opportunities and lowers manufacturing costs, it is expected to achieve significant EBITDA margin stabilization around 34-35% by 2026, which will contribute to strong free cash flow and enhance balance sheet flexibility.

Bears say

Globus Medical faces significant risks that contribute to a negative outlook, including slower-than-expected growth in the spine market and potential revenue disruption from recent mergers with NuVasive and Nevro. The bear case scenario suggests a bleak revenue growth forecast of low single digits, accompanied by flat margins and heightened downside risks from competitive dynamics and underperformance of key product launches. Additionally, the potential for declining operating margins and challenges in market expansion within the musculoskeletal space raise further concerns about the company's financial stability.

Globus Medical (GMED) has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 42% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Globus Medical (GMED) Forecast

Analysts have given Globus Medical (GMED) a Buy based on their latest research and market trends.

According to 12 analysts, Globus Medical (GMED) has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $99.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $99.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Globus Medical (GMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.